Anti-infective therapy for infections caused by drug-resistant gram-negative pathogens now in Phase I study

By NewsDesk @infectiousdiseasenews Biopharmaceutical company, Qpex Biopharma, announced this week the initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections caused by drug-resistant gram-negative pathogens. Infections due to multidrug-resistant (MDR) Acinetobacter sp. and Pseudomonas aeruginosa have resulted in an increased reliance on polymyxin antibiotics originally discovered over 60 [...]

The post Anti-infective therapy for infections caused by drug-resistant gram-negative pathogens now in Phase I study appeared first on Outbreak News Today.